The field of use
of the drug Mexidol®
The use of Mexidol® is effective in therapy of acute and chronic cerebrovascular diseases caused by ischemia and hypoxia of various genesis. To date, the drug is one of the main products of basic neuroprotective brain therapy due to the multimodal mechanism of action, which provides a wide range of pharmacological effects. Mexidol® is successfully used in various fields of medicine: neurology, therapy, ophthalmology, cardiology, neuropediatry, psychiatry and narcology.
Acute cerebrovascular disorders
Stroke is an acute cerebrovascular impairment, causing damage and the death of nerve cells. The stroke is characterized by sudden (within a few minutes, hours) by the appearance of focal and/or common neurological symptoms, which persists for more than 24 hours or leads to the death of the patient in a shorter period of time due to cerebrovascular pathology. The use of Mexidol® in the acute period of ischemic stroke at the prehospital stage, followed by thrombolytic therapy, has a positive effect on a decrease in neurological deficiency, regardless of the severity of the disease. Mexidol® confirmed its effectiveness and safety in numerous studies. The study of Epic proved a decrease in the severity of neurological deficiency and an improvement in the quality of life of patients when using the drug Mexidol® in the complex therapy of ischemic stroke in the acute and early recovery periods.
Chronic
brain ischemia
Chronic brain ischemia is a slowly progressive structural and functional change in the brain. Such a change occurs due to diffuse and/or small cudbow damage to the brain tissue in conditions of long -existing insufficiency of cerebral blood supply. An important component of the treatment of chronic brain ischemia is the prescription of drugs with multimodal effects with antioxidant, anti -hyphyxant and neuroprotective activity.
A bright representative of multimodal neuroprotectors is Mexidol® (original ethylmethylhydroxypyridine succinate). The drug showed a high degree of efficiency and safety in an international multicenter randomized double blind, a placebo-controlled study of patients with chronic brain ischemia (memo study).
Cognitive disorders
against the background of arterial hypertension
Chronic brain ischemia is a slowly progressive structural and functional change in the brain. Such a change occurs due to diffuse and/or small cudbow damage to the brain tissue in conditions of long -existing insufficiency of cerebral blood supply. An important component of the treatment of chronic brain ischemia is the prescription of drugs with multimodal effects with antioxidant, anti -hyphyxant and neuroprotective activity.
A bright representative of multimodal neuroprotectors is Mexidol® (original ethylmethylhydroxypyridine succinate). The drug showed a high degree of efficiency and safety in an international multicenter randomized double blind, a placebo-controlled study of patients with chronic brain ischemia (memo study).
Attention deficit syndrome
in children
Chronic brain ischemia is a slowly progressive structural and functional change in the brain. Such a change occurs due to diffuse and/or small cudbow damage to the brain tissue in conditions of long -existing insufficiency of cerebral blood supply. An important component of the treatment of chronic brain ischemia is the prescription of drugs with multimodal effects with antioxidant, anti -hyphyxant and neuroprotective activity.
A bright representative of multimodal neuroprotectors is Mexidol® (original ethylmethylhydroxypyridine succinate). The drug showed a high degree of efficiency and safety in an international multicenter randomized double blind, a placebo-controlled study of patients with chronic brain ischemia (memo study).
* For ADHD, Mexidol tablets covered with a film membrane are used, 125 mg.
Information is intended for medical and pharmaceutical workers. This information cannot serve as a replacement for a doctor’s consultation.
Source of photos and images Shutterstock.com